Michelle McMurry-Heath | |
|---|---|
 McMurry-Heath in 2020 | |
| Education | Harvard University (BS) Duke University (MD, PhD) |
| Scientific career | |
| Fields | Health policy |
| Institutions | Biotechnology Innovation Organization, Johnson & Johnson, Food and Drug Administration |
Michelle McMurry-Heath is a medical doctor, immunologist, and from June 2020 until October 2022 served as Chief executive officer for the Biotechnology Innovation Organization (BIO).
McMurry-Heath was born and raised in Oakland, California. [1] Her mother was a public health nurse, and her father was a psychologist. [1]
After first pursuing a double major in art history and psychology during college, she changed her focus to biochemistry and received an undergraduate degree from Harvard University in biochemistry. [1] She is the first Black graduate of the Duke University combined MD / Ph.D. Medical Scientist Training Program, and completed her Ph.D. in immunology. [1] [2]
After completing her education, McMurry-Heath worked in research for 12 years. [3] After training from the Robert Wood Johnson Foundation, she shifted to science policy, which included work from 2001 to 2004 as a legislative aide for Senator Joe Lieberman and drafting a bioterrorism preparedness bill in 2002. [1] [3] [4]
During her work with the Aspen Institute, she was a founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program. [4] She also worked as an adjunct assistant professor of health policy at George Washington University. [4] In 2010, she became the associate director at the Center for Devices and Radiological Health at the Food and Drug Administration. [1] In this role, she developed partnerships with medical device nonprofits. [5]
Towards the end of 2014, she became an executive at Johnson & Johnson and her management role later expanded. [1] [6] While at Johnson & Johnson, she was advised by Michael D. Watkins, who continued as an advisor after she moved to her role as president and CEO of the Biotechnology Innovation Organization (BIO). [1]
She has previously worked with the Council on Foreign Relations. [7] From 2018 to 2020, she was Chair of the NESTcc Governing Committee. [8] She is a member of the AAAS Committee on Science, Engineering and Public Policy (COSEPP). [9]
In June 2020, McMurry-Heath became the chief executive of the Biotechnology Innovation Organization (BIO), a lobbying organization that represents several hundred biotech companies, [1] [10] [11] including most of the companies that developed COVID-19 vaccines, [12] as well as academic institutions. [13] At BIO, she led the Coronavirus Collaboration Initiative, a group focused on developing COVID-19 vaccines and treatments. [14] In 2021, she was named as a possible nominee to lead the Food and Drug Administration. [15] [16] [17]
McMurry-Heath resigned from her role as CEO of BIO effective October 11, 2022, and she continues to serve as an advisor to the board. [18] [19]
McMurry-Heath is married to Sebastian Heath, a veterinarian. They have one daughter and currently live in Washington, D.C. [7]
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 50% of all vaccines manufactured in the world. With industry standards compliant mega production capabilities and large number of skilled domestic workforce, Indian exports meet the standards and requirements of highly regulated markets of USA, UK, European Union and Canada. According to the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, domestic pharmaceutical market turnover reached Rs 129,015 crore in 2018, growing 9.4 per cent year-on-year and exports revenue was US$17.28 billion in FY18 and US$19.14 billion in FY19.
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Patrick Soon-Shiong is an American transplant surgeon, billionaire businessman, bioscientist, and media proprietor. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.
The Biomedical Advanced Research and Development Authority(BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.
Margaret Ann "Peggy" Hamburg is an American physician and public health administrator, who is serving as the chair of the board of the American Association for the Advancement of Science (AAAS) and co-chair of the InterAcademy Partnership (IAP). She served as the 21st Commissioner of the U.S. Food and Drug Administration from May 2009 to April 2015.
Brett P. Giroir is an American pediatrician. He was formerly the U.S. assistant secretary for health, a four-star admiral in the U.S. Public Health Service Commissioned Corps and an acting Food and Drug Administration commissioner.
Sara Radcliffe is an American medical research advocate and business executive. She is the president and CEO of California Life Sciences Association, a non-profit organization that advocates for the medical research mission of the life sciences sector of California. She is best known for her expertise in the field of applied public health and an advocate for life sciences.
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry.
Roivant Sciences is a healthcare company focused on applying technology to drug development. Roivant builds subsidiary biotech and healthcare technology companies.
Janet Woodcock is an American physician and former Acting Commissioner of the U.S. Food and Drug Administration (FDA). She joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as the Director of Center for Drug Evaluation and Research (CDER) from 1994 to 2004 and 2007 to 2021.
Shenzhen International BT Leadership Summit is a biology-focused business conference. It is held each year in September. It is arranged by the Shenzhen Municipal People's Government. It is held at the Shenzhen Convention and Exhibition Center.
The Bill & Melinda Gates Medical Research Institute is a non-profit biotechnology organization founded with the aim of bringing technologies and strategies to bear on the main health problems of the poor in low-income countries. The Gates MRI was organized as a subsidiary of the Bill & Melinda Gates Foundation who funded it with a $273 million 4-year grant.
Richard Hatchett is an American oncologist and epidemiologist who has been serving as chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI) in Oslo and London since 2017. He was awarded the Secretary of Health and Human Services's Award for Distinguished Service.
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.
Albert Bourla is a Greek-American veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.
Drew Weissman is an American physician-scientist best known for his contributions to RNA biology. His work helped enable development of mRNA vaccines, the best known of which are those for COVID-19 produced by BioNTech/Pfizer and Moderna. Weissman is the inaugural Roberts Family Professor in Vaccine Research, Director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn). He and his research colleague Katalin Karikó have received numerous awards including the presigious Lasker-DeBakey Clinical Medical Research Award.
{{cite book}}: |author2= has generic name (help)